Aurora Cannabis Inc. (OTCQB: ACBFF) announced on June 7th that the company has signed an agreement with Capcium Inc. for a production line of cannabis-based softgel medication for patients. In addition to this agreement announcement, Aurora acquired a 19.99% ownership stake in Capcium through a $10 million investment.
Capcium is one of the world’s leading manufacturers in softgels. Additionally, the company is leading the rest of the industry with highly precise cannabis softgels.
Aurora’s investment into Capcium will be used to expand cannabis softgel production through the construction and operation of a new facility. The new facility will be state-of-the-art and is scheduled to be completed in or by Q4 of 2019.
The two companies have decided and agreed to begin immediately on this partnership by establishing a softgel manufacturing site at Aurora’s facility in Pointe-Clair, Quebec.
The facility, Aurora Vie, will be introducing softgels for sale into the Canadian cannabis market near the end of the summer of 2018.